Smith & Nephew plc
SNNHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Smith & Nephew plc focuses on Medical Devices services and products. Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. Valued at $12.90B, SNN is a large-cap name in its sector. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Market Cap
$12.90B
Beta
0.67
P/E (TTM)
20.97
P/E (Fwd)
12.80
EPS (TTM)
$1.47
EPS (Fwd)
$2.41
ROE
11.8%
ROA
5.2%
Cash
$754.0M
Total Debt
$3.78B
Free CF
$1.06B
52W Change
-15.7%
Annual Financials
Cash vs Debt
Where SNN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SNN finished 3.19% below its 150-day moving average ($29.79) and 6.12% below its 200-day moving average ($30.72). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SNN overbought or oversold?
At the October 20, 2026 close, SNN's RSI(14) was 81.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Smith & Nephew plc carries $3.78B in total debt against $754.0M in cash reserves — debt is roughly 5.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $1.06B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 11.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $5.21B to $6.16B.
With a beta below 0.7, Smith & Nephew plc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Smith & Nephew plc carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing SNN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.